Uric acid is associated with the rate of residual renal function decline in peritoneal dialysis patients

Nephrology Dialysis Transplantation

Volumn 24, Issue 11, 2009, Pages 3520-3525

  Park, Jung Tak ^a   Kim, Dong Ki ^a   Chang, Tae Ik ^a   Kim, Hyun Wook ^a   Chang, Jae Hyun ^a   Park, Sun Young ^a   Kim, Eunyoung ^a   Kang, Shin Wook ^a   Han, Dae Suk ^a   Yoo, Tae Hyun ^a  

^a Yonsei University College of Medicine   (South Korea)

Author keywords

End stage renal disease; Hypertension; Peritoneal dialysis; Residual renal function; Uric acid

Indexed keywords

CREATININE; UREA; URIC ACID;

ADULT; ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DIABETES MELLITUS; FEMALE; FUNCTIONAL RESIDUAL CAPACITY; HUMAN; HYPERTENSION; HYPERURICEMIA; KIDNEY FAILURE; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; PERITONEAL DIALYSIS; PRIORITY JOURNAL; AGED; BLOOD; CHRONIC KIDNEY FAILURE; CONTINUOUS AMBULATORY PERITONEAL DIALYSIS; KIDNEY; MIDDLE AGED; PATHOPHYSIOLOGY;

ADULT; AGED; FEMALE; HUMANS; HYPERTENSION; HYPERURICEMIA; KIDNEY; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; PERITONEAL DIALYSIS, CONTINUOUS AMBULATORY; URIC ACID;

EID: 73949134999     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfp272     Document Type: Article

References (32)

1. Nakagawa T, Kang DH, Feig D et al. Unearthing uric acid: an ancient factor with recently found significance in renal and cardiovascular disease. Kidney Int 2006; 69: 1722-1725
2. Suliman ME, Johnson RJ, Garcia-Lopez E et al. J-shaped mortality relationship for uric acid in CKD. Am J Kidney Dis 2006; 48: 761-771
3. Mazzali M, Hughes J, Kim YG et al. Elevated uric acid increases blood pressure in the rat by a novel crystal-independent mechanism. Hypertension 2001; 38: 1101-1106
4. Sanchez-Lozada LG, Tapia E, Santamaria J et al. Mild hyper-uricemia induces vasoconstriction and maintains glomerular hypertension in normal and remnant kidney rats. Kidney Int 2005; 67: 237-247
5. Mazzali M, Kanellis J, Han L et al. Hyperuricemia induces a primary renal arteriolopathy in rats by a blood pressure-independent mechanism. Am J Physiol Renal Physiol 2002; 282: F991-F997
6. Kang DH, Park SK, Lee IK et al. Uric acid-induced C-reactive protein expression: implication on cell proliferation and nitric oxide production of human vascular cells. J Am Soc Nephrol 2005; 16: 3553-3562
7. Khosla UM, Zharikov S, Finch JL et al. Hyperuricemia induces en-dothelial dysfunction. Kidney Int 2005; 67: 1739-1742
8. Sundstrom J, Sullivan L, D'Agostino RB et al. Relations of serum uric acid to longitudinal blood pressure tracking and hypertension incidence. Hypertension 2005; 45: 28-33
9. Iseki K, Oshiro S, Tozawa M et al. Significance of hyperuricemia on the early detection of renal failure in a cohort of screened subjects. Hypertens Res 2001; 24: 691-697.
10. Segura J, Campo C, Ruilope LM. How relevant and frequent is the presence of mild renal insufficiency in essential hypertension? J Clin Hypertens (Greenwich) 2002; 4: 332-336
11. Syrjanen J, Mustonen J, Pasternack A. Hypertriglyceridaemia and hyperuricaemia are risk factors for progression of IgA nephropathy. Nephrol Dial Transplant 2000; 15: 34-42
12. Tseng CH. Correlation of uric acid and urinary albumin excretion rate in patients with type 2 diabetes mellitus in Taiwan. Kidney Int 2005; 68: 796-801
13. Nolph KD, Moore HL, Prowant B et al. Cross sectional assessment of weekly urea and creatinine clearances and indices of nutrition in continuous ambulatory peritoneal dialysis patients. Perit Dial Int. 1993; 13: 178-183
14. Shin SK, Noh H, Kang SW et al. Risk factors influencing the decline of residual renal function in continuous ambulatory peritoneal dialysis patients. Perit Dial Int. 1999; 19: 138-142
15. Ifudu O, Tan CC, Dulin AL et al. Gouty arthritis in end-stage renal disease: clinical course and rarity of new cases. Am J Kidney Dis 1994; 23: 347-351
16. Iseki K, Ikemiya Y, Inoue T et al. Significance of hyperuricemia as a risk factor for developing ESRD in a screened cohort. Am J Kidney Dis 2004; 44: 642-650
17. Kanellis J, Watanabe S, Li JH et al. Uric acid stimulates monocyte chemoattractant protein-1 production in vascular smooth muscle cells via mitogen-activated protein kinase and cyclooxygenase-2. Hypertension 2003; 41: 1287-1293
18. Kang DH, Nakagawa T, Feng L et al. A role for uric acid in the progression of renal disease. J Am Soc Nephrol 2002; 13: 2888-2897
19. Armstrong KA, Johnson DW, Campbell SB et al. Does uric acid have a pathogenetic role in graft dysfunction and hypertension in renal transplant recipients? Transplantation 2005; 80: 1565-1571
20. Weiner DE, Tighiouart H, Elsayed EF et al. Uric acid and incident kidney disease in the community. J Am Soc Nephrol 2008; 19: 1204-1211
21. Bargman JM, Thorpe KE, Churchill DN. Relative contribution of residual renal function and peritoneal clearance to adequacy of dialysis: a reanalysis of the CANUSA study. J Am Soc Nephrol 2001; 12: 2158-2162
22. Canaud B. Residual renal function: the delicate balance between benefits and risks. Nephrol Dial Transplant 2008; 23: 1801-1805
23. Han SH, Lee SC, Ahn SV et al. Reduced residual renal function is a risk of peritonitis in continuous ambulatory peritoneal dialysis patients. Nephrol Dial Transplant 2007; 22: 2653-2658
24. Li PK, Cheng YL. Therapeutic options for preservation of residual renal function in patients on peritoneal dialysis. Perit Dial Int 2007; 27(Suppl 2): S158-S163
25. Van Biesen W, Lameire N, Verbeke F et al. Residual renal function and volume status in peritoneal dialysis patients: a conflict of interest? J Nephrol 2008; 21: 299-304
26. Rocco M, Soucie JM, Pastan S et al. Peritoneal dialysis adequacy and risk of death. Kidney Int 2000; 58: 446-457
27. Paniagua R, Amato D, Vonesh E et al. Effects of increased peritoneal clearances on mortality rates in peritoneal dialysis: ADEMEX, a prospective, randomized, controlled trial. J Am Soc Nephrol 2002; 13: 1307-1320
28. Lysaght MJ, Vonesh EF, Gotch F et al. The influence of dialysis treatment modality on the decline of remaining renal function. ASAIO Trans 1991; 37: 598-604
29. Davies SJ, Phillips L, Naish PF et al. Quantifying comorbidity in peritoneal dialysis patients and its relationship to other predictors of survival. Nephrol Dial Transplant 2002; 17: 1085-1092
30. Moist LM, Port FK, Orzol SM et al. Predictors of loss of residual renal function among new dialysis patients. J Am Soc Nephrol 2000; 11: 556-564
31. Fan SL, Pile T, Punzalan S et al. Randomized controlled study of biocompatible peritoneal dialysis solutions: effect on residual renal function. Kidney Int 2008; 73: 200-206
32. Williams JD, Topley N, Craig KJ et al. The Euro-Balance Trial: the effect of a new biocompatible peritoneal dialysis fluid (balance) on the peritoneal membrane. Kidney Int 2004; 66: 408-418